LivaNova (NASDAQ:LIVN) Reaches New 1-Year High – Time to Buy?

LivaNova PLC (NASDAQ:LIVN)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $74.32 and last traded at $72.8950, with a volume of 801796 shares changing hands. The stock had previously closed at $72.23.

Analysts Set New Price Targets

Several research firms have commented on LIVN. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Barclays upped their price target on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Mizuho upped their price target on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Robert W. Baird decreased their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

LivaNova Stock Up 0.9%

The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The business has a fifty day simple moving average of $64.58 and a two-hundred day simple moving average of $63.13. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of 37.38 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts expect that LivaNova PLC will post 3.72 EPS for the current year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after acquiring an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares in the last quarter. Intech Investment Management LLC boosted its holdings in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after acquiring an additional 7,195 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of LivaNova in the 1st quarter worth approximately $130,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.